SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Anna Klukowska, Krystyna Zawilska, Koncentraty czynników krzepnięcia o przedłużonym działaniu w leczeniu hemofilii, Acta Haematologica Polonica, 2015,

    CrossRef

  2. 2
    K. Kavakli, R. Yang, L. Rusen, H. Beckmann, D. Tseneklidou-Stoeter, M. Maas Enriquez, Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II), Journal of Thrombosis and Haemostasis, 2015, 13, 3
  3. 3
    G. Young, J. Mahlangu, R. Kulkarni, B. Nolan, R. Liesner, J. Pasi, C. Barnes, S. Neelakantan, G. Gambino, L. M. Cristiano, G. F. Pierce, G. Allen, Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A, Journal of Thrombosis and Haemostasis, 2015, 13, 5
  4. 4
    C. Kessler, J. Oldenburg, C. Escuriola Ettingshausen, A. Tiede, K. Khair, C. Négrier, R. Klamroth, Spotlight on the human factor: building a foundation for the future of haemophilia A management, Haemophilia, 2015, 21,
  5. 5
    Rolf Ljung, Nadine Gretenkort Andersson, The current status of prophylactic replacement therapy in children and adults with haemophilia, British Journal of Haematology, 2015, 169, 5
  6. 6
    K. Khair, Compliance, concordance and adherence: what are we talking about?, Haemophilia, 2014, 20, 5
  7. 7
    Lukas Fliedl, Johannes Grillari, Regina Grillari-Voglauer, Human cell lines for the production of recombinant proteins: on the horizon, New Biotechnology, 2014,

    CrossRef

  8. 8
    Anna Klukowska, Jak wybrać koncentrat czynnika krzepnięcia dla dziecka chorego na hemofilię?, Acta Haematologica Polonica, 2014, 45, 1, 49

    CrossRef